Inventurus Knowledge Solutions (IKS) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
6 Jan, 2026Executive summary
Achieved strong Q4 FY25 and full-year results, with significant revenue and margin growth, outpacing market growth rates despite headwinds from customer base rationalization and business model transformation.
Five strategic execution pillars: AI-led platform evolution, AQuity acquisition integration, feature leadership, differentiated growth strategies by segment, and outcome-based business model.
Deep client relationships with over 450 enterprise customers and high revenue concentration from top clients, with increasing diversification.
Recognized as industry leader with multiple awards for clinical documentation, medical coding, and AI-driven RCM.
The group operates a single business segment: a care enablement platform for healthcare providers.
Financial highlights
Q4 FY25 revenue grew 17% year-on-year to INR 724 crore (INR 7,240 mn), with EBITDA up 68% to INR 226 crore and PAT up 133%.
FY25 revenue reached INR 2,664 crore (INR 26,640 mn), up 47% year-on-year, with EBITDA at INR 791 crore and PAT at INR 486 crore (31.2% growth).
Q4 FY25 EBITDA margin at 31.2%, PAT margin at 20.4%; FY25 EBITDA margin at 29.7%, PAT margin at 18.2%.
EPS for FY25: INR 29.20, up from INR 22.37 in FY24.
Operating cash flow for FY25 was INR 434 crore (INR 4,340 mn); free cash flow was INR 275 crore (INR 2,750 mn).
Outlook and guidance
Management expects to grow faster than the 12% outsourced TAM growth rate but refrains from providing specific quarterly or annual guidance due to market immaturity.
Ongoing investments in technology and workforce to support scale and margin improvement, with further cross-sell and tech-led transformation expected.
The figures for FY24 include results from Aquity Holdings Inc, acquired on October 27, 2023, making year-over-year comparisons not fully comparable.
Latest events from Inventurus Knowledge Solutions
- Q3 FY26 saw 24% revenue growth, 40%+ EBITDA growth, and strong cash generation.IKS
Q3 25/265 Feb 2026 - Q2 FY26 delivered strong growth, margin expansion, and strategic investment in healthcare tech.IKS
Q2 25/263 Feb 2026 - 16% revenue growth, 31% EBITDA margin, and major client wins marked Q3 FY25.IKS
Q3 24/259 Jan 2026 - Q1 FY26 saw double-digit revenue and profit growth, margin expansion, and strong cash flow.IKS
Q1 25/266 Jan 2026